According to WuShuo, biotech company Sonnet BioTherapeutics (NASDAQ: SONN) announced that its shareholders have officially approved the business merger with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC. The transaction had previously been filed under Form S-4, and after the merger is completed, HSI is planned to be listed on Nasdaq. The company will submit the final voting results to the SEC via Form 8-K. Previously, Hyperliquid Strategies filed an S-1 document, aiming to raise up to $1 billion, potentially for purchasing HYPE tokens. https://www.(wublock123.com)/index.php?m=content&c=index&a=show&catid=6&id=52834